The Nomination Committee for Elicera Therapeutics proposes re-election of Board
Gothenburg, January 14, 2022 – Elicera Therapeutics AB (publ), a clinical stage cell and gene therapy company that develops immuno-oncological treatments focused on CAR T-cells and oncolytic viruses, announces that the nomination committee has agreed on a proposal for the Annual General Meeting in March 2022. On April 26 2021, the Annual General Meeting established rules to guide the work of the Nomination Committee. The three largest owners at September 30 were Magnus Essand, Di Yu and Jamal El-Mosleh, controlling 47.1% of the votes, have earlier been appointed as nomination